ClinicalTrials.gg
CompletedNCT01381809Updated Mar 16, 2016

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

A Phase 3 interventional study of Group 2: Placebo and Group 1: Epoetin alfa in Myelodysplastic Syndromes, sponsored by Janssen-Cilag International NV. Completed at 28 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-16.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes — 2 open to participants now, 4 under way, 2 of them phase 3. Epoetin Alfa · Myelodysplastic Syndromes.

Started
2011
the only one that year
Phase 3
5 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Janssen-Cilag International NV

Among the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, this one is the only one that started in 2011, is one of 5 in phase 3, and was the 7th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

2 of the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that epoetin alfa works better than placebo in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). The safety of epoetin alfa will also be evaluated.

Read the detailed description

This is a randomized (the treatment you receive will be assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled (comparison with patients that receive treatment without active ingredient), multicenter study of epoetin alfa in anemic patients who are diagnosed with myelodysplastic syndromes (MDS) according to protocol-specified criteria. This study includes a 3-week prerandomization phase, a 24-week treatment phase and a 24-week treatment extension phase. All patients enrolled in the study will complete an end-of-study visit 4 weeks after the last dose of study drug (Week 28 or Week 52), or 4 weeks after early withdrawal (unless the reason for early withdrawal is withdrawal of consent). Between 125 and 159 patients will be enrolled in the treatment phase of the study. During the screening phase, which will take place within 2 weeks before starting study drug, the study doctor will do tests to see if the patient is suitable for this study. Patients meeting entry criteria for the study will then be randomly assigned to one of the 2 treatment groups. This means that each patient who is allowed to join the study is put into a group by chance, like flipping a coin. Group 1 patients will receive epoetin alfa 450 or increased up to 1050 International Units (IU) per kg body weight administered by subcutaneous injection (injection beneath the skin) using pre-filled syringes. Injections will be done once every week at a weight-based dose regimen (the total weekly dose received will depend on your weight) with a possible total maximum dose of 40,000 IU once every week for the first 8 weeks of the treatment phase and 80,000 IU once every week at any other time during the study. Group 2 patients will receive a matching volume of placebo administered once every week by subcutaneous injection. The chance that the patient will get epoetin alfa is 2 to 1. Doses of study drug will be withheld, decreased, or increased on the basis of erythroid response, weekly hemoglobin concentrations monitored in patients and predefined dose adjustment guidelines. Patients will see the study doctor every 4 weeks for a period of 24 weeks. At each visit the patient will undergo a full hematologic evaluation, serum chemistry evaluation, measurement of blood pressure and pulse rate, recording of blood product transfusions and transfusion complications, adverse events, concomitant therapies and an evaluation for disease progression. The patient's Erythroid response will be assessed at Week 8 and every 4 weeks thereafter, until Week 24. Blinded study treatment will be administered to all patients at Week 24. However, at the end of the treatment phase (after the Week 24 response assessment), only responders will enter the double-blind treatment extension phase to measure the duration of response. Patients will continue to receive the same treatment, in the same blinded fashion, and at the same dose as received at Week 24, and will return to the study center every 4 weeks, until Week 48, for assessment of the Erythroid response and the evaluations as described above. For all non-responders at Week 24 the treatment code will be broken after Week 28 assessments. For responders at Week 48, the treatment code will be broken after the Week 48 visit, following completion of the response assessment. The treatment code will not be broken for subjects who discontinue study treatment before Week 24, irrespective of whether they are responders or nonresponders. For these subjects, the blind will not be broken until all subjects have completed the study and the database is final. Once the patient stops receiving doses of study drug, he/she will be asked to see the study doctor for the safety follow-up visit, which is scheduled 4 weeks after the last dose of study drug. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by physical examination, laboratory tests and evaluation of adverse events. An Independent Data Monitoring Committee (IDMC) will periodically review study data and for the assessment of disease progression. The total duration of study participation will be for about 30 or 54 weeks.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Bone Marrow disease
  • Anemia
  • Epoetin Alfa
  • Eprex
  • Erypo
  • Erythropoiesis-stimulating agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MDS according to World Health Organization or French-American-British pathologic classification (confirmed via bone marrow aspirate/) within 12 weeks prior to screening
  • Documentation of an International Prognostic Scoring System score indicating Low- or Intermediate-1-risk disease within 12 weeks prior to screening
  • concentration at screening and baseline (before the first dose of study drug) of 10.0 g/dL or less
  • Screening serum erythropoietin concentration of less than 500 mU/mL
  • Red Blood Cell transfusion requirement of less than or equal to 4 red blood cell units over the last 8 weeks before randomization

Exclusion criteria

Exclusion Criteria:

  • Anemia attributed to factors other than MDS (including hemolysis, chronic renal failure, hepatitis, gastrointestinal bleeding)
  • Secondary MDS (ie, MDS arising after chemotherapy, immunotherapy or radiation therapy/exposure)
  • History of , except in situ skin basal cell carcinoma or carcinoma in situ of the cervix or breast curatively treated
  • Prior therapy with any erythropoiesis-stimulating agent (ESA) (including innovative ESAs and biosimilar ESAs for approved indications or for use) in the last 8 weeks before randomization
  • Prior use of approved or experimental agents for the treatment of MDS
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Epoetin alfa

    Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks

    Drug: Group 1: Epoetin alfa

  • Placebo comparator
    No treatment

    Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks

    Drug: Group 2: Placebo

Interventions

  • DrugGroup 2: Placebo

    form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks

  • type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks

06

What researchers measure

Primary outcomes

  1. Erythroid response

    Time frame: at week 24

Secondary outcomes

  1. Maintenance of Erythroid response

    Time frame: every 4 weeks from week 24 to week 48

  2. Duration of response

    Time frame: every 4 weeks after week 24

  3. Time to first Red Blood Cell transfusion

    Time frame: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)

  4. Transfusion-free intervals

    Time frame: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)

  5. Number of Red Blood Cell units transfused

    Time frame: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)

  6. Quality of life as measured by Functional Assessment of Cancer Therapy-Anemia/Fatigue (FACT-An) questionnaire

    Time frame: at baseline, week 24 and week 48

  7. Quality of life as measured by EuroQol 5-dimension (EQ-5D) questionnaire

    Time frame: at baseline, week 24 and week 48

  8. Drug consumption

    Time frame: every 4 weeks from baseline to week 48

  9. Duration of hospitalization

    Time frame: every 4 weeks from baseline to week 48

  10. Number and duration of medical care encounters

    Time frame: every 4 weeks from baseline to week 48

07

Study locations

28 sites
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Amiens, France
  • Angers Cedex 9, France
  • Bobigny, France
  • Colmar, France
  • Paris Cedex 10, France
  • Pessac Cedex, France
  • Pierre Benite Cedex, France
  • Saint Priest En Jarez, France
  • Tours Cedex 9, France
  • Vandoeuvre Les Nancy, France
  • Berlin, Germany
  • Dresden, Germany
  • Duisburg, Germany
  • Düsseldorf, Germany
  • Dÿsseldorf, Germany
  • München, Germany
  • Oldenburg, Germany
  • Würzburg, Germany
  • Athens, Greece
  • Goudi-Athens, Greece
  • Larisa, Greece
  • Patra, Greece
  • Thessalonikis, Greece
  • Ekaterinburg, Russian Federation
  • St. Petersburg, Russian Federation
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 27, 2011
Start
Oct 2011
Primary completionActual
Jan 2015
CompletionActual
Jan 2016
Last update
Mar 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01381809
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Oct 2011
Primary completion
Jan 2015
Completion
Jan 2016
Last update
Mar 16, 2016

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion